News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,989 Results
Type
Article (8064)
Company Profile (140)
Press Release (476784)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166812)
Career Advice (304)
Deals (25744)
Drug Delivery (7)
Drug Development (52944)
Employer Resources (14)
FDA (9787)
Job Trends (8577)
News (238352)
Policy (17917)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33185)
ALS (105)
Alzheimer's disease (977)
Antibody-drug conjugate (ADC) (264)
Approvals (10407)
Artificial intelligence (321)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3652)
Cardiovascular disease (218)
Career advice (245)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47946)
Collaboration (1250)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (762)
CRISPR (63)
C-suite (751)
Cystic fibrosis (86)
Data (5678)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4188)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73744)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87647)
Executive appointments (701)
FDA (12427)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (920)
Gene editing (125)
Generative AI (9)
Gene therapy (318)
GLP-1 (291)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9331)
Hematology (94)
HIV (61)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (955)
Inflammatory bowel disease (127)
Inflation Reduction Act (4)
Influenza (86)
Intellectual property (256)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (61)
Legal (5198)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (535)
Marketing (8)
MASH (118)
Medical device (8657)
Medtech (8802)
Mergers & acquisitions (14390)
Metabolic disorders (709)
mRNA (55)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1828)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (508)
Peanut (31)
People (41253)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15477)
Phase 2 (21407)
Phase 3 (14444)
Pipeline (7361)
Policy (19)
Postmarket research (1579)
Preclinical (6540)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3020)
Recruiting (6)
Regulatory (14850)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (50)
Vaccines (325)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (46)
Last 7 days (215)
Last 30 days (1585)
Last 365 days (19070)
2026 (12363)
2025 (19277)
2024 (23006)
2023 (26553)
2022 (34601)
2021 (37179)
2020 (33487)
2019 (23273)
2018 (17484)
2017 (18774)
2016 (17931)
2015 (24281)
2014 (21697)
2013 (18142)
2012 (20223)
2011 (20450)
2010 (20335)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17956)
Australia (2098)
California (11992)
Canada (3149)
China (524)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24731)
Florida (1789)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (700)
India (51)
Indiana (314)
Iowa (15)
Japan (422)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7861)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2622)
New Mexico (12)
New York (2822)
North Carolina (1282)
North Dakota (4)
Northern California (6006)
Ohio (278)
Oklahoma (14)
Oregon (16)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4983)
Tennessee (120)
Texas (1942)
United States (38908)
Utah (360)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,989 Results for "shionogi inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
July 16, 2026
·
6 min read
Press Releases
Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS
July 30, 2026
·
8 min read
Press Releases
Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*
July 28, 2026
·
16 min read
Press Releases
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
April 2, 2026
·
9 min read
Press Releases
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
May 14, 2026
·
11 min read
Press Releases
Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026
April 17, 2026
·
7 min read
Press Releases
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
June 2, 2026
·
14 min read
Press Releases
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
April 2, 2026
·
7 min read
Press Releases
Shionogi Receives Contract with U.S. Government Through BARDA’s Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
April 8, 2026
·
11 min read
Press Releases
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
March 19, 2026
·
8 min read
1 of 48,499
Next
